Overview

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: AEE788 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving AEE788 together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of AEE788 when given together with everolimus and to see how well they work in treating patients with recurrent or relapsed glioblastoma multiforme.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Everolimus
Sirolimus